Paclitaxel
Paclitaxel 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Breast Neoplasms、Triple Negative Breast Neoplasms、HR Low-Positive/HER2-Negative Breast Neoplasms、Gastric or Gastroesophageal Junction Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
3 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- Phanes Therapeutics
- Kochi University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- UNC Lineberger Comprehensive Cancer Center
- Shanghai Kechow Pharma, Inc.
- The First Affiliated Hospital of Zhengzhou University
- Medical University of South Carolina
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
- Teva Pharmaceuticals, Inc.
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
日本、中国、美国、法国、德国、Malaysia、Poland、South Korea、西班牙、中国台湾、英国、Argentina
正在招募患者的 Paclitaxel 研究
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
II 期 / III 期招募中日本NCT05268692Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
II 期招募中中国NCT05941338Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
III 期招募中中国NCT06008106Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
II 期招募中中国NCT05738434Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
II 期招募中中国NCT04807140A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
II 期招募中美国NCT07743190Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
II 期招募中中国NCT06467617PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
II 期招募中美国NCT06245889NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
I 期招募中中国NCT05881525Pucotenlimab and Anlotinib in Combination With Chemotherapy
II 期招募中中国NCT07896668Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
II 期招募中美国NCT06745882Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
II 期招募中美国NCT04992780A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
I 期 / II 期招募中中国NCT06840002A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
I 期 / II 期招募中美国中国法国德国NCT06385080A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
III 期招募中美国ArgentinaChile中国NCT07022483Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma
I 期招募中中国台湾NCT06229496A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
II 期招募中中国NCT07108270AB122 Platform Study
I 期招募中日本NCT04999761Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
II 期招募中中国NCT06818331Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
II 期招募中比利时NCT06962137Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
不适用招募中中国NCT05620095Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
II 期招募中中国NCT07635342Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
II 期招募中中国NCT06586242
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。